ERBB2 and cancer: These receptors define four phenotypes: luminal A and B cancers, which are positive for ER and PR and negative for HER2, basal-like cancer, which is positive for HER2 and negative for ER and PR and, finally, triple-negative cancers, negative for the three receptors [21].